報價延遲最少15分鐘:2024/12/23 22:13 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.499899 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.40/-11.43
|
|
企業價值
3.50M
|
| 資產負債 |
|
每股賬面淨值
-0.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. |